围生期心肌病的药物干预。
Pharmacological interventions for peripartum cardiomyopathy.
机构信息
Second Department of Obstetrics and Gynecology, Aretaieion University Hospital, National and Kapodistrian University of Athens, Athens, Greece.
Obstetrics, Gynecology and Reproductive Medicine Working Group, Society of Junior Doctors, Athens, Greece.
出版信息
Cochrane Database Syst Rev. 2024 Oct 30;10(10):CD014851. doi: 10.1002/14651858.CD014851.
Abstract
This is a protocol for a Cochrane Review (intervention). The objectives are as follows: To assess the effectiveness and safety of available pharmacological interventions for the care of women diagnosed with PPCM.
摘要
这是一篇 Cochrane 综述（干预措施）的方案。其目的如下：评估现有药物干预措施在 PPCM 女性患者护理中的有效性和安全性。
相似文献
1
Pharmacological interventions for peripartum cardiomyopathy.围生期心肌病的药物干预。
Cochrane Database Syst Rev. 2024 Oct 30;10(10):CD014851. doi: 10.1002/14651858.CD014851.
2
Peripartum cardiomyopathy - a cardiovascular disease in pregnancy and puerperium. The actual state of knowledge, challenges, and perspectives.围产期心肌病——一种发生于妊娠和产褥期的心血管疾病。知识现状、挑战及展望。
Ginekol Pol. 2021;92(2):147-152. doi: 10.5603/GP.a2020.0171. Epub 2020 Oct 21.
3
The Medical Treatment of New-Onset Peripartum Cardiomyopathy: A Systematic Review of Prospective Studies.新发围产期心肌病的医学治疗：前瞻性研究的系统评价
Can J Cardiol. 2015 Dec;31(12):1421-6. doi: 10.1016/j.cjca.2015.04.029. Epub 2015 May 2.
4
Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy.一项评估溴隐亭对围产期心肌病女性左心室功能影响的随机对照多中心临床试验的原理与设计。
Clin Res Cardiol. 2015 Nov;104(11):911-7. doi: 10.1007/s00392-015-0869-5. Epub 2015 May 31.
5
Treatment of Peripartum Cardiomyopathy: A Call to Action.围产期心肌病的治疗：行动呼吁
Can J Cardiol. 2015 Dec;31(12):1418-20. doi: 10.1016/j.cjca.2015.05.025. Epub 2015 Jul 9.
6
[Peripartum cardiomyopathy].[围产期心肌病]
Ugeskr Laeger. 2009 Jan 5;171(1-2):53-5.
7
Peripartum Cardiomyopathy with the Cardiac Function Restored by Cabergoline.产后心肌病经卡麦角林治疗后心功能恢复
Intern Med. 2023 Jul 15;62(14):2085-2088. doi: 10.2169/internalmedicine.0988-22. Epub 2022 Nov 23.
8
Review of Randomized Controlled Trials in Patients with Peripartum Cardiomyopathy.围生期心肌病患者的随机对照试验研究综述。
Curr Cardiol Rev. 2023;19(2):e230822207933. doi: 10.2174/1573403X18666220823151854.
9
Peripartum Cardiomyopathy Treatment with Dopamine Agonist and Subsequent Pregnancy with a Satisfactory Outcome.使用多巴胺激动剂治疗围产期心肌病及随后妊娠并获得满意结局
Rev Bras Ginecol Obstet. 2016 Jun;38(6):308-13. doi: 10.1055/s-0036-1584567. Epub 2016 Jul 11.
10
Impact of autoantibodies against the M2-muscarinic acetylcholine receptor on clinical outcomes in peripartum cardiomyopathy patients with standard treatment.抗 M2 毒蕈碱型乙酰胆碱受体自身抗体对标准治疗围生期心肌病患者临床结局的影响。
BMC Cardiovasc Disord. 2021 Dec 28;21(1):619. doi: 10.1186/s12872-021-02414-7.
本文引用的文献
1
Long-Term Outcomes of Women With Peripartum Cardiomyopathy Having Subsequent Pregnancies.围生期心肌病患者再次妊娠的长期结局。
J Am Coll Cardiol. 2023 Jul 4;82(1):16-26. doi: 10.1016/j.jacc.2023.04.043.
2
Transcriptomic Comparison of Human Peripartum and Dilated Cardiomyopathy Identifies Differences in Key Disease Pathways.人类围产期心肌病与扩张型心肌病的转录组学比较揭示关键疾病通路的差异。
J Cardiovasc Dev Dis. 2023 Apr 23;10(5):188. doi: 10.3390/jcdd10050188.
3
Incidence, Risk Factors, Maternal and Neonatal Outcomes of Peripartum Cardiomyopathy (PPCM) in Oman.阿曼围生期心肌病（PPCM）的发病率、危险因素、母婴结局。
Glob Heart. 2023 May 2;18(1):23. doi: 10.5334/gh.1198. eCollection 2023.
4
Thromboembolic events in peripartum cardiomyopathy: Results from the ESC EORP PPCM registry.围产期心肌病中的血栓栓塞事件：欧洲心脏病学会围产期心肌病注册研究结果
Eur J Heart Fail. 2023 Aug;25(8):1464-1466. doi: 10.1002/ejhf.2871. Epub 2023 May 29.
5
Meta-Analysis of Long-Term (>1 Year) Cardiac Outcomes of Peripartum Cardiomyopathy.围产期心肌病长期（>1年）心脏结局的Meta分析
Am J Cardiol. 2023 May 1;194:71-77. doi: 10.1016/j.amjcard.2023.01.043. Epub 2023 Mar 28.
6
Peripartum Cardiomyopathy: Current Understanding of Pathophysiology, Diagnostic Workup, Management, and Outcomes.围生期心肌病：病理生理学、诊断方法、治疗和结局的最新认识。
Curr Probl Cardiol. 2023 Aug;48(8):101716. doi: 10.1016/j.cpcardiol.2023.101716. Epub 2023 Mar 25.
7
Screening for peripartum cardiomyopathies using artificial intelligence in Nigeria (SPEC-AI Nigeria): Clinical trial rationale and design.尼日利亚使用人工智能筛查围产期心肌病（SPEC-AI Nigeria）：临床试验原理和设计。
Am Heart J. 2023 Jul;261:64-74. doi: 10.1016/j.ahj.2023.03.008. Epub 2023 Mar 25.
8
A new risk score for the assessment of outcomes for Chinese patients with peripartum cardiomyopathy.一种用于评估中国围生期心肌病患者结局的新风险评分。
Heart Lung. 2023 Jul-Aug;60:81-86. doi: 10.1016/j.hrtlng.2023.02.021. Epub 2023 Mar 16.
9
Prognostic Value of Cardiac MRI Late Gadolinium Enhancement in Patients with Peripartum Cardiomyopathy: A Retrospective Study.围生期心肌病患者心脏磁共振钆延迟增强的预后价值：一项回顾性研究。
Curr Probl Cardiol. 2023 Apr;48(4):101587. doi: 10.1016/j.cpcardiol.2023.101587. Epub 2023 Jan 9.
10
Geographic disparities in peripartum cardiomyopathy outcomes.围生期心肌病结局的地理差异。
Am J Obstet Gynecol MFM. 2023 Feb;5(2):100788. doi: 10.1016/j.ajogmf.2022.100788. Epub 2022 Oct 27.
Zotero 插件